CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8). It has an IC50 of 5 nM and 7 nM in H929 multiple myeloma (MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively. It is for research use only and not sold to patients.
- Special cyclin-dependent kinase 9 (CDK9) inhibitor.
- Extracted from patent WO/2012131594A1, compound CDKI(8).
- IC50 of 5 nM in H929 multiple myeloma (MM) cell line (72 hours).
- IC50 of 7 nM in A2058 skin cell line (72 hours).
- Reduces expression of MEPCE.
- Reduces MCL1 protein expression.
- Appearance: solid, light yellow to yellow.
- Effective in inhibiting CDK9 activity.
- Has antiproliferative activity against various cell lines including 4T1, A498, A549, AD293, BT-549, HK-2, HeLa, HepG2, Hs-578T, L02, MCF-10A, MDA-MB-231, and MRC5.